menu
    • menu
    [{"orgOrder":0,"company":"Essential Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Haloperidol Decanoate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Essential Pharma \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Essential Pharma"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Essential Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Colistimethate Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Essential Pharma \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Essential Pharma"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Hu14.18K322A","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essential Pharma \/ Essential Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ Essential Pharma"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Galantamine Hydrobromide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Essential Pharma \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Essential Pharma"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Apraclonidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Essential Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Essential Pharma

    Menu

    Essential Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma

                            Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).

                            Product Name : Hu14.18K322A

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 11, 2024

                            Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essential Pharma Acquires Reminyl® (galantamine hydrobromide) Capsules

                            Details : Essential Pharma has acquired rights to Reminyl (galantamine), a cholinesterase inhibitor, for the EEA, Thailand, South Korea, and other markets, excluding the UK and Japan.

                            Product Name : Reminyl

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 17, 2024

                            Lead Product(s) : Galantamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hu14.18K322A

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Renaissance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essential Pharma Acquires Renaissance Pharma's Immunotherapy for High-Risk Neuroblastoma

                            Details : Through the acquisition, Essential Pharma will leverage Renaissance clinical-stage immunotherapy product Hu14.18 (Hu14.18K322A) for the treatment of high-risk neuroblastoma.

                            Product Name : Hu14.18

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 09, 2024

                            Lead Product(s) : Hu14.18K322A

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Renaissance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essential Pharma Acquires European Rights to Colobreathe®(colistimethate sodium) from Teva

                            Details : Essential Pharma acquired rights to Colobreathe (colistimethate sodium) for managing chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients across Europe.

                            Product Name : Colobreathe

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            French Marketing Authorization for Iopidine® 1% (Apraclodinin) Transferred to Essential Pharma in Line with T...

                            Details : Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, a sympathomimetic used in glaucoma therapy. It is used as a short-term adjunctive therapy in open-angle glaucoma who are on maximally tolerated medical therapy requiring additional ...

                            Product Name : Iopidine

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 16, 2023

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UK Marketing Authorisations for IOPIDINE® (apraclonidine) Fully Transferred to Essential Pharma as Change in ...

                            Details : IOPIDINE (apraclonidine hydrochloride), is a short-term adjunctive therapy for chronic glaucoma to prevent or control intraocular pressure including after selective laser therapy, a form of laser eye surgery now recommended as the initial treatment for o...

                            Product Name : Iopidine

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Haloperidol Decanoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essential Pharma Announces the Acquisition of HALDOL®

                            Details : HALDOL® (haloperidol decanoate) is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions such as schizoaffective disorder and moderate to severe manic episodes associated with bipolar I d...

                            Product Name : Haldol

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : Haloperidol Decanoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essential Pharma Expands Global Portfolio with Ocular and Postpartum Acquisitions

                            Details : Essential pharma acquires Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, for the adjunctive treatment of glaucoma and Methergine for treating post-partum haemorrhage.

                            Product Name : Iopidine

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 16, 2021

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth